苏州玉森新药与四川现代中药创新技术公司缔结战略联盟 加速推进中药1.1类创新药研发进程

Core Insights - Suzhou Yusen Pharmaceutical Development Co., Ltd. and Sichuan Modern Traditional Chinese Medicine Innovation Technology Co., Ltd. signed a product cooperation agreement to collaborate on two innovative traditional Chinese medicine products, "Xiaoxian Zhihuan Oral Liquid" and "Tiandan Dingxuan Granules" [1][2] - The partnership aims to enhance the research and industrialization of traditional Chinese medicine, integrating resources across technology, clinical research, registration, and post-market promotion [1][2] Group 1 - "Xiaoxian Zhihuan Oral Liquid" targets children aged 3-7 with adenoid hypertrophy, utilizing ingredients like Platycodon and Houttuynia to clear heat and resolve phlegm, filling a gap in the traditional Chinese medicine market [2] - "Tiandan Dingxuan Granules" is designed for treating dizziness caused by phlegm and wind, featuring core ingredients such as Gastrodia and Salvia, addressing the growing demand for dizziness treatment in an aging population [2] - Both products are expected to enter clinical trials by 2026, targeting a market of 4 billion for adenoid hypertrophy and 1.2 billion for dizziness, showcasing the unique characteristics of traditional Chinese medicine with minimal side effects [2] Group 2 - The collaboration is seen as a synergy of technology and industry, creating a complete innovation loop from laboratory research to clinical application [2] - Future plans include exploring international registration of traditional Chinese medicine and the development of health products, contributing to the construction of a collaborative innovation corridor between Sichuan and Suzhou [2]